Wolverine Asset Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Wolverine Asset Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-35,056	Closed	-$2.24K	–	2362
2022 Q4	$2.24K	Hold	35,056	–	–	﹤0.01%	1857
2022 Q3	$2K	Hold	35,056	–	–	﹤0.01%	2300
2022 Q2	$3K	Buy	35,056 +514	+1%	+$106	﹤0.01%	2210
2022 Q1	$8K	Hold	34,542	–	–	﹤0.01%	1957
2021 Q4	$22K	Sell	34,542 -17,088	-33%	-$11.9K	﹤0.01%	1702
2021 Q3	$34K	Sell	51,630 -12,166	-19%	-$9.05K	﹤0.01%	1514
2021 Q2	$54K	Buy	+63,796	New	+$44.3K	﹤0.01%	1650

Wolverine Asset Management's BIOTW Position: Q1 2023 in Review

Wolverine Asset Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 35,056 shares — an estimated $2.24K sold.

Wolverine Asset Management first reported a position in BIOTW in Q2 2021 and held it in 7 quarters. The position peaked at $54K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Wolverine Asset Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Wolverine Asset Management sold 35,056 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $2.24K.
Wolverine Asset Management first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 7 quarters.
Wolverine Asset Management's Biotech Acquisition Company Warrant position peaked at $54K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.